These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 31306860)

  • 41. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.
    Mintzer JE; Tune LE; Breder CD; Swanink R; Marcus RN; McQuade RD; Forbes A
    Am J Geriatr Psychiatry; 2007 Nov; 15(11):918-31. PubMed ID: 17974864
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intramuscular aripiprazole in the control of agitation.
    Currier GW; Citrome LL; Zimbroff DL; Oren D; Manos G; McQuade R; Pikalov AA; Crandall DT
    J Psychiatr Pract; 2007 May; 13(3):159-69. PubMed ID: 17522559
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients.
    Lesem MD; Zajecka JM; Swift RH; Reeves KR; Harrigan EP
    J Clin Psychiatry; 2001 Jan; 62(1):12-8. PubMed ID: 11235922
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Liquid risperidone in the treatment of psychotic agitation.
    Tsai C; Puzantian T
    CNS Drugs; 2002; 16(11):777; author reply 778. PubMed ID: 12383033
    [No Abstract]   [Full Text] [Related]  

  • 45. Brief report: risperidone for severely disturbed behavior and tardive dyskinesia in developmentally disabled adults.
    Khan BU
    J Autism Dev Disord; 1997 Aug; 27(4):479-89. PubMed ID: 9261670
    [No Abstract]   [Full Text] [Related]  

  • 46. Efficacy of betaxolol in neuroleptic-induced akathisia.
    Adler LA; Angrist B; Rotrosen J
    Psychiatry Res; 1991 Nov; 39(2):193-8. PubMed ID: 1686812
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia.
    Breier A; Meehan K; Birkett M; David S; Ferchland I; Sutton V; Taylor CC; Palmer R; Dossenbach M; Kiesler G; Brook S; Wright P
    Arch Gen Psychiatry; 2002 May; 59(5):441-8. PubMed ID: 11982448
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Administration of high dose haloperidol in a patient refractory to treatment with traditional and atypical neuroleptics].
    Stip E; Bruneau MA
    Encephale; 1996; 22(4):298-300. PubMed ID: 9035986
    [No Abstract]   [Full Text] [Related]  

  • 49. Comparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in Taiwan.
    Hsu WY; Huang SS; Lee BS; Chiu NY
    J Clin Psychopharmacol; 2010 Jun; 30(3):230-4. PubMed ID: 20473056
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of the agitation of late-life psychosis and Alzheimer's disease.
    Salzman C
    Eur Psychiatry; 2001 Jan; 16 Suppl 1():25s-28s. PubMed ID: 11520475
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Duration of risperidone treatment for BPSD.
    Snowdon J; Brodaty H; Ames D; Day S
    Int J Geriatr Psychiatry; 2006 Jul; 21(7):699-701. PubMed ID: 16821255
    [No Abstract]   [Full Text] [Related]  

  • 52. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder.
    Goff DC; Posever T; Herz L; Simmons J; Kletti N; Lapierre K; Wilner KD; Law CG; Ko GN
    J Clin Psychopharmacol; 1998 Aug; 18(4):296-304. PubMed ID: 9690695
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia.
    Wright P; Birkett M; David SR; Meehan K; Ferchland I; Alaka KJ; Saunders JC; Krueger J; Bradley P; San L; Bernardo M; Reinstein M; Breier A
    Am J Psychiatry; 2001 Jul; 158(7):1149-51. PubMed ID: 11431240
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rapid tranquilization with intramuscular clonazepam.
    Benazzi F; Mazzoli M
    Can J Psychiatry; 1994 Sep; 39(7):451. PubMed ID: 7987793
    [No Abstract]   [Full Text] [Related]  

  • 55. Anticholinergic agents for prophylaxis of neuroleptic-induced dystonic reactions: a prospective study.
    Sramek JJ; Simpson GM; Morrison RL; Heiser JF
    J Clin Psychiatry; 1986 Jun; 47(6):305-9. PubMed ID: 2872206
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Psychopharmacology in psychiatric emergencies.
    Extein I
    Int J Psychiatry Med; 1980-1981; 10(3):189-204. PubMed ID: 6108296
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dementia update. Pharmacologic management of agitation and psychosis in older demented patients.
    Zaraa AS
    Geriatrics; 2003 Oct; 58(10):48-50, 52-3. PubMed ID: 14569642
    [No Abstract]   [Full Text] [Related]  

  • 58. A naturalistic comparison study of the efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular levomepromazine in acute agitated patients with schizophrenia.
    Suzuki H; Gen K; Takahashi Y
    Hum Psychopharmacol; 2014 Jan; 29(1):83-8. PubMed ID: 24424709
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Injectable atypical antipsychotics for agitation in borderline personality disorder.
    Pascual JC; Madre M; Soler J; Barrachina J; Campins MJ; Alvarez E; Pérez V
    Pharmacopsychiatry; 2006 May; 39(3):117-8. PubMed ID: 16721704
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Neuroleptic malignant syndrome].
    Bryois C; Bondolfi G
    Rev Med Suisse Romande; 1996 Sep; 116(9):713-7. PubMed ID: 8966472
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.